Rollout Map
Sign Up
H.R. 8205 House Health

Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026

Became Law
Introduced
Apr 6, 2026
Sponsor
Rep. Quigley, Mike (D-IL-5)
View on Congress.gov

BECAME LAW NOV 3, 2026

Became Law on Nov 3, 2026.

  1. House Introduced in House Apr 6, 2026
  2. House Referred to the House Committee on Energy and Commerce. Apr 6, 2026
  3. House Referred to the Subcommittee on Health. Apr 6, 2026
  4. House Subcommittee Consideration and Mark-up Session Held May 13, 2026
  5. House Forwarded by Subcommittee to Full Committee by Voice Vote. May 13, 2026
  6. House Committee Consideration and Mark-up Session Held May 21, 2026
  7. House Ordered to be Reported (Amended) by the Yeas and Nays: 46 - 0. May 21, 2026
  8. House Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 119-733. Jul 9, 2026
  9. House Placed on the Union Calendar, Calendar No. 637. Jul 9, 2026
  10. House Mr. Guthrie moved to suspend the rules and pass the bill, as amended. Jul 20, 2026
  11. House Considered under suspension of the rules. (consideration: CR H4652-4654; text: CR H4653) Jul 20, 2026
  12. House DEBATE - The House proceeded with forty minutes of debate on H.R. 8205. Jul 20, 2026
  13. House At the conclusion of debate, the chair put the question on the motion to suspend the rules. Mr. Guthrie objected to the vote on the grounds that a quorum was not present. Further proceedings on the motion were postponed. The point of no quorum was considered as withdrawn. Jul 20, 2026
  14. House Considered as unfinished business. (consideration: CR H5159) Jul 22, 2026
  15. House Considered as unfinished business. Jul 22, 2026
  16. House Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. Jul 22, 2026
  17. House On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. Jul 22, 2026
  18. House Motion to reconsider laid on the table Agreed to without objection. Jul 22, 2026
  19. Senate Received in the Senate. Read twice. Placed on Senate Legislative Calendar under General Orders. Calendar No. 466. Jul 23, 2026
  20. House Passed/agreed to in Senate: Passed Senate without amendment by Voice Vote. (consideration: CR S5120) Sep 28, 2026
  21. Senate Passed Senate without amendment by Voice Vote. (consideration: CR S5120) Sep 28, 2026
  22. Senate Message on Senate action sent to the House. Oct 14, 2026
  23. House
    Presented to President. Oct 26, 2026
  24. House
    Signed by President. Nov 3, 2026
  25. House Latest action
    Became Public Law No: 119-138. Nov 3, 2026

Cosponsors

103

Subjects

Department of Health and Human ServicesDrug therapyFood and Drug Administration (FDA)Government information and archivesHealth programs administration and fundingInternet, web applications, social mediaMedical researchNational Institutes of Health (NIH)Neurological disordersPublic-private cooperationResearch administration and funding

Committees

  • Energy and Commerce Committee
    • [Reported By, Jul 9, 2026]
    • [Markup By, May 21, 2026]
    • [Referred To, Apr 6, 2026]

Summary

Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026This act reauthorizes through FY2031 and revises programs that support research and development of drugs and other therapies to address amyotrophic lateral sclerosis (also known as ALS or Lou Gehrig's disease) and other neurodegenerative diseases.The act reauthorizesgrants from the National Institutes of Health (NIH) for scientific research on investigational drugs to prevent or treat ALS for individuals not otherwise eligible for clinical trials,grants from the Food and Drug Administration (FDA) for research and development of therapies to prevent and treat ALS and other neurodegenerative diseases, anda Public-Private Partnership including the FDA and NIH that supports development and regulatory review of treatments for neurodegenerative diseases. Also, the NIH, in considering renewal of its grants, must assess available information on the safety and efficacy of the investigational drugs. It must also require grantees to promptly report serious and unexpected adverse events associated with their investigational drugs.Additionally, the FDA must publish a plan describing actions it will take over a five-year period to foster development of safe and effective drugs, and facilitate access to investigational drugs, that treat ALS and other rare neurodegenerative diseases. The FDA must also publish a report describing the actions it has taken under the plan.

[Summary as of: Public Law]

Bill Text

Formatted Text PDF United States Legislative Markup Formatted XML

Related Bills

Comments · 0

Loading comments...